PMID- 36910649
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230314
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Comparing efficacy and safety of first-line treatment of metastatic renal cell 
      carcinoma: A Bayesian network meta-regression analysis.
PG  - 1072634
LID - 10.3389/fonc.2023.1072634 [doi]
LID - 1072634
AB  - BACKGROUND: This Bayesian network meta-regression analysis provides a 
      head-to-head comparison of first-line therapeutic immune checkpoint inhibitors 
      (ICI) and tyrosine kinase inhibitors (TKI) combinations for metastatic renal cell 
      carcinoma (mRCC) using median follow-up time as covariate. METHODS: We searched 
      Six databases for a comprehensive analysis of randomised clinical trials (RCTs). 
      Comparing progression free survival (PFS) and overall survival (OS) of different 
      interventions at the same time node by Bayesian network meta-analysis. Bayesian 
      network meta-regression analysis was performed on objective response rate (ORR), 
      adverse events (AEs) (grade >/= 3) and the hazard ratios (HR) associated with PFS 
      and OS, with the median follow-up time as the covariate. RESULTS: Eventually a 
      total of 22 RCTs reporting 11,090 patients with 19 interventions. Lenvatinib plus 
      Pembrolizumab (LenPem) shows dominance of PFS, and Pembrolizumab plus Axitinib 
      (PemAxi) shows superiority in OS at each time point. After meta-regression 
      analysis, for HRs of PFS, LenPem shows advantages; for HRs of OS, PemAxi shows 
      superiority; For ORR, LenPem provides better results. For AEs (grade >/= 3), 
      Atezolizumab plus Bevacizumab (AtezoBev) is better. CONCLUSION: Considering the 
      lower toxicity and the higher quality of life, PemAxi should be recommended as 
      the optimal therapy in treating mRCC. SYSTEMATIC REVIEW REGISTRATION: 
      https://www.crd.york.ac.uk/prospero/, identifier CRD4202236775.
CI  - Copyright (c) 2023 Qin, Xv, Chen, Wang, Lu, Li, Guo, Yang, Liu, Wang and Wang.
FAU - Qin, Suyang
AU  - Qin S
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      National Clinical Research Center for Chinese Medicine Acupuncture and 
      Moxibustion, Tianjin, China.
FAU - Xv, Zhiyuan
AU  - Xv Z
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      National Clinical Research Center for Chinese Medicine Acupuncture and 
      Moxibustion, Tianjin, China.
FAU - Chen, Xi
AU  - Chen X
AD  - School of Health, Brooks College, Sunnyvale, CA, United States.
AD  - Department of Epidemiology and Statistics, School of Public Health, Medical 
      College, Zhejiang University, Hangzhou, China.
FAU - Wang, Shurui
AU  - Wang S
AD  - School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical 
      College, Beijing, China.
FAU - Lu, Hai
AU  - Lu H
AD  - Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Li, Jiaqi
AU  - Li J
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      National Clinical Research Center for Chinese Medicine Acupuncture and 
      Moxibustion, Tianjin, China.
FAU - Guo, Xinglin
AU  - Guo X
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      National Clinical Research Center for Chinese Medicine Acupuncture and 
      Moxibustion, Tianjin, China.
FAU - Yang, Jinghua
AU  - Yang J
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      National Clinical Research Center for Chinese Medicine Acupuncture and 
      Moxibustion, Tianjin, China.
FAU - Liu, Chengjiang
AU  - Liu C
AD  - Department of Gastroenterology, Anhui Medical University, Hefei, China.
FAU - Wang, Yaoguang
AU  - Wang Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      National Clinical Research Center for Chinese Medicine Acupuncture and 
      Moxibustion, Tianjin, China.
FAU - Wang, Hongwu
AU  - Wang H
AD  - School of Health Sciences and Engineering, Tianjin University of Traditional 
      Chinese Medicine, Tianjin, China.
LA  - eng
PT  - Systematic Review
DEP - 20230222
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9992527
OTO - NOTNLM
OT  - efficacy
OT  - immune checkpoint inhibitors
OT  - metastatic renal cell carcinoma
OT  - network meta-regression analysis
OT  - tyrosine kinase inhibitors
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/14 06:00
MHDA- 2023/03/14 06:01
PMCR- 2023/01/01
CRDT- 2023/03/13 04:15
PHST- 2022/10/31 00:00 [received]
PHST- 2023/02/10 00:00 [accepted]
PHST- 2023/03/13 04:15 [entrez]
PHST- 2023/03/14 06:00 [pubmed]
PHST- 2023/03/14 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1072634 [doi]
PST - epublish
SO  - Front Oncol. 2023 Feb 22;13:1072634. doi: 10.3389/fonc.2023.1072634. eCollection 
      2023.